Gyulladásos bélbetegségben szenvedo gyermekek kezelésének átadása felnottszakrendelésre: 10 éves tapasztalataink összegzése

Translated title of the contribution: Transfer of care of adolescent inflammatory bowel disease patients without longitudinal transition: Lesson from 10 years experiences

Szántó Kata, Szucs Dániel, Vass Noémi, Várkonyi Ágnes, Bálint Anita, Bor Renáta, Fábián Anna, Milassin Ágnes, Rutka Mariann, Szepes Zoltán, F. Nagy, T. Molnár, Farkas Klaudia

Research output: Contribution to journalArticle

Abstract

Introduction: Transfer is a planned movement of patients and their medical records from one provider to another. Only a few data are available from real life in inflammatory bowel disease patients in this topic. Aim: Our aim was to retrospectively evaluate the results of the transfer of our patients without longitudinal transition. Method: Data of the transferred patients at the University of Szeged were analysed. Patients were diagnosed in paediatric care. Transfer strategy at our departments was detailed medical summary. Results: 59 patients were enrolled in this study. 28.8% of the patients had mild to moderate disease activity and 71.2% was in remission at the time of transfer. Steroid therapy was initiated in 58% of the patients within an average of 9.1 months after the transfer. Anti-tumor necrosis factor therapy was given to 24% of the patients during the paediatric care and to an additional 23% in the adult care within an average of 28 months. Almost 70% of the patients received immunosuppressive therapy during paediatric and adult care. Surgery was required in 17% of the patients within an average 10.7 months after the transfer. Conclusion: Our results revealed that one-third of the paediatric patients have been transferred to adult care in active stage of disease. Shortly after the transfer 58% of the patients required corticosteroids and 17% surgery. Every fifth patient needed biological therapy to be initiated after the transfer. Longitudinal transition may have a potential to decrease the need for therapeutic change and the relatively high rate of surgery.

Original languageHungarian
Pages (from-to)1789-1793
Number of pages5
JournalOrvosi Hetilap
Volume159
Issue number44
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Inflammatory Bowel Diseases
Pediatrics
Patient Transfer
Biological Therapy
Therapeutics
Immunosuppressive Agents
Medical Records
Adrenal Cortex Hormones
Tumor Necrosis Factor-alpha
Steroids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gyulladásos bélbetegségben szenvedo gyermekek kezelésének átadása felnottszakrendelésre : 10 éves tapasztalataink összegzése. / Kata, Szántó; Dániel, Szucs; Noémi, Vass; Ágnes, Várkonyi; Anita, Bálint; Renáta, Bor; Anna, Fábián; Ágnes, Milassin; Mariann, Rutka; Zoltán, Szepes; Nagy, F.; Molnár, T.; Klaudia, Farkas.

In: Orvosi Hetilap, Vol. 159, No. 44, 01.11.2018, p. 1789-1793.

Research output: Contribution to journalArticle

Kata, S, Dániel, S, Noémi, V, Ágnes, V, Anita, B, Renáta, B, Anna, F, Ágnes, M, Mariann, R, Zoltán, S, Nagy, F, Molnár, T & Klaudia, F 2018, 'Gyulladásos bélbetegségben szenvedo gyermekek kezelésének átadása felnottszakrendelésre: 10 éves tapasztalataink összegzése', Orvosi Hetilap, vol. 159, no. 44, pp. 1789-1793. https://doi.org/10.1556/650.2018.31198
Kata, Szántó ; Dániel, Szucs ; Noémi, Vass ; Ágnes, Várkonyi ; Anita, Bálint ; Renáta, Bor ; Anna, Fábián ; Ágnes, Milassin ; Mariann, Rutka ; Zoltán, Szepes ; Nagy, F. ; Molnár, T. ; Klaudia, Farkas. / Gyulladásos bélbetegségben szenvedo gyermekek kezelésének átadása felnottszakrendelésre : 10 éves tapasztalataink összegzése. In: Orvosi Hetilap. 2018 ; Vol. 159, No. 44. pp. 1789-1793.
@article{5658767442da42efaafeb94deb7a3dd2,
title = "Gyullad{\'a}sos b{\'e}lbetegs{\'e}gben szenvedo gyermekek kezel{\'e}s{\'e}nek {\'a}tad{\'a}sa felnottszakrendel{\'e}sre: 10 {\'e}ves tapasztalataink {\"o}sszegz{\'e}se",
abstract = "Introduction: Transfer is a planned movement of patients and their medical records from one provider to another. Only a few data are available from real life in inflammatory bowel disease patients in this topic. Aim: Our aim was to retrospectively evaluate the results of the transfer of our patients without longitudinal transition. Method: Data of the transferred patients at the University of Szeged were analysed. Patients were diagnosed in paediatric care. Transfer strategy at our departments was detailed medical summary. Results: 59 patients were enrolled in this study. 28.8{\%} of the patients had mild to moderate disease activity and 71.2{\%} was in remission at the time of transfer. Steroid therapy was initiated in 58{\%} of the patients within an average of 9.1 months after the transfer. Anti-tumor necrosis factor therapy was given to 24{\%} of the patients during the paediatric care and to an additional 23{\%} in the adult care within an average of 28 months. Almost 70{\%} of the patients received immunosuppressive therapy during paediatric and adult care. Surgery was required in 17{\%} of the patients within an average 10.7 months after the transfer. Conclusion: Our results revealed that one-third of the paediatric patients have been transferred to adult care in active stage of disease. Shortly after the transfer 58{\%} of the patients required corticosteroids and 17{\%} surgery. Every fifth patient needed biological therapy to be initiated after the transfer. Longitudinal transition may have a potential to decrease the need for therapeutic change and the relatively high rate of surgery.",
keywords = "Inflammatory bowel diseases, Patient transfer, Transitional care",
author = "Sz{\'a}nt{\'o} Kata and Szucs D{\'a}niel and Vass No{\'e}mi and V{\'a}rkonyi {\'A}gnes and B{\'a}lint Anita and Bor Ren{\'a}ta and F{\'a}bi{\'a}n Anna and Milassin {\'A}gnes and Rutka Mariann and Szepes Zolt{\'a}n and F. Nagy and T. Moln{\'a}r and Farkas Klaudia",
year = "2018",
month = "11",
day = "1",
doi = "10.1556/650.2018.31198",
language = "Hungarian",
volume = "159",
pages = "1789--1793",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "44",

}

TY - JOUR

T1 - Gyulladásos bélbetegségben szenvedo gyermekek kezelésének átadása felnottszakrendelésre

T2 - 10 éves tapasztalataink összegzése

AU - Kata, Szántó

AU - Dániel, Szucs

AU - Noémi, Vass

AU - Ágnes, Várkonyi

AU - Anita, Bálint

AU - Renáta, Bor

AU - Anna, Fábián

AU - Ágnes, Milassin

AU - Mariann, Rutka

AU - Zoltán, Szepes

AU - Nagy, F.

AU - Molnár, T.

AU - Klaudia, Farkas

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Introduction: Transfer is a planned movement of patients and their medical records from one provider to another. Only a few data are available from real life in inflammatory bowel disease patients in this topic. Aim: Our aim was to retrospectively evaluate the results of the transfer of our patients without longitudinal transition. Method: Data of the transferred patients at the University of Szeged were analysed. Patients were diagnosed in paediatric care. Transfer strategy at our departments was detailed medical summary. Results: 59 patients were enrolled in this study. 28.8% of the patients had mild to moderate disease activity and 71.2% was in remission at the time of transfer. Steroid therapy was initiated in 58% of the patients within an average of 9.1 months after the transfer. Anti-tumor necrosis factor therapy was given to 24% of the patients during the paediatric care and to an additional 23% in the adult care within an average of 28 months. Almost 70% of the patients received immunosuppressive therapy during paediatric and adult care. Surgery was required in 17% of the patients within an average 10.7 months after the transfer. Conclusion: Our results revealed that one-third of the paediatric patients have been transferred to adult care in active stage of disease. Shortly after the transfer 58% of the patients required corticosteroids and 17% surgery. Every fifth patient needed biological therapy to be initiated after the transfer. Longitudinal transition may have a potential to decrease the need for therapeutic change and the relatively high rate of surgery.

AB - Introduction: Transfer is a planned movement of patients and their medical records from one provider to another. Only a few data are available from real life in inflammatory bowel disease patients in this topic. Aim: Our aim was to retrospectively evaluate the results of the transfer of our patients without longitudinal transition. Method: Data of the transferred patients at the University of Szeged were analysed. Patients were diagnosed in paediatric care. Transfer strategy at our departments was detailed medical summary. Results: 59 patients were enrolled in this study. 28.8% of the patients had mild to moderate disease activity and 71.2% was in remission at the time of transfer. Steroid therapy was initiated in 58% of the patients within an average of 9.1 months after the transfer. Anti-tumor necrosis factor therapy was given to 24% of the patients during the paediatric care and to an additional 23% in the adult care within an average of 28 months. Almost 70% of the patients received immunosuppressive therapy during paediatric and adult care. Surgery was required in 17% of the patients within an average 10.7 months after the transfer. Conclusion: Our results revealed that one-third of the paediatric patients have been transferred to adult care in active stage of disease. Shortly after the transfer 58% of the patients required corticosteroids and 17% surgery. Every fifth patient needed biological therapy to be initiated after the transfer. Longitudinal transition may have a potential to decrease the need for therapeutic change and the relatively high rate of surgery.

KW - Inflammatory bowel diseases

KW - Patient transfer

KW - Transitional care

UR - http://www.scopus.com/inward/record.url?scp=85056264393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056264393&partnerID=8YFLogxK

U2 - 10.1556/650.2018.31198

DO - 10.1556/650.2018.31198

M3 - Article

C2 - 30392410

AN - SCOPUS:85056264393

VL - 159

SP - 1789

EP - 1793

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 44

ER -